We recently announced that our MagSense® diagnostic technology has the potential to target prostate cancer tumors, making this the second cancer type the technology has
https://youtu.be/iH0a08glQYo Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity MELBOURNE — Imagion
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense® Systems for early
This article represents the viewpoint of management. MagSense® technology is taking a leading position amidst a broad trend in cancer medicine toward finding out more,
Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense®
In this second segment of Bob Proulx’s presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be
Here are the principal “slide deck” visuals used to introduce Imagion Biosystems to investors prior to the company’s initial public offering on the Australian Securities Exchange. (download
Data from the US National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, charted below, illustrates the critical importance of early cancer detection. Earlier diagnosis
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
